Comparative methods for quantifying plasma biomarkers in Alzheimer's disease: Implications for the next frontier in cerebral amyloid angiopathy diagnostics

Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke

(2023) Nicholas J. Reish et al.   NEW ENGLAND JOURNAL OF MEDICINE

Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy

(2023) Yu Guo et al.   npj Parkinsons Disease

Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy

(2023) Jochen A Sembill et al.   Brain Communications

Progression of cerebral amyloid angiopathy: a pathophysiological framework

(2023) Emma A Koemans et al.   LANCET NEUROLOGY

Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults

(2022) Pierre‐François Meyer et al.   ANNALS OF NEUROLOGY

Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy

(2022) Leonidas Chouliaras et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis

(2022) Nils G. Margraf et al.   Frontiers in Aging Neuroscience

Amyloid-Related Imaging Abnormalities and β-Amyloid–Targeting Antibodies

(2022) Massimo Filippi et al.   JAMA Neurology

Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change

(2022) Denis S. Smirnov et al.   ACTA NEUROPATHOLOGICA

Biofluid‐based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature

(2022) Henrik Zetterberg   Alzheimers & Dementia

Association of plasma biomarkers, p‐tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long‐term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years

(2022) Hannah Stocker et al.   Alzheimers & Dementia

Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, Aβ42, and Aβ40 in Probable Cerebral Amyloid Angiopathy

(2022) Lou Grangeon et al.   JOURNAL OF ALZHEIMERS DISEASE

A Multi-Dimensional Comparison of Alzheimer’s Disease Neurodegenerative Biomarkers

(2022) Ying Liu et al.   JOURNAL OF ALZHEIMERS DISEASE

Cerebrospinal Fluid Biomarkers for Cerebral Amyloid Angiopathy Diagnosis

(2022) Andreas Charidimou   JOURNAL OF ALZHEIMERS DISEASE

Plasma Aβ as a biomarker for predicting Aβ-PET status in Alzheimer’s disease：a systematic review with meta-analysis

(2022) Lizhen Cheng et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217

(2022) Colin Groot et al.   Alzheimers Research & Therapy

β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer’s disease and predicts cerebral amyloidosis

(2022) Tao-Ran Li et al.   Alzheimers Research & Therapy

Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment

(2022) Yan Hu et al.   JAMA Network Open

Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity

(2022) Stephen Zicha et al.   Alzheimers & Dementia

An accurate fully automated panel of plasma biomarkers for Alzheimer's disease

(2022) Sebastian Palmqvist et al.   Alzheimers & Dementia

The Role of Amyloid-β, Tau, and α-Synuclein Proteins as Putative Blood Biomarkers in Patients with Cerebral Amyloid Angiopathy

(2022) Rebecca Piccarducci et al.   JOURNAL OF ALZHEIMERS DISEASE

The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study

(2022) Andreas Charidimou et al.   LANCET NEUROLOGY

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

(2022) Shorena Janelidze et al.   BRAIN

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease

(2022) Michael J. Pontecorvo et al.   JAMA Neurology

Lecanemab in Early Alzheimer’s Disease

(2022) Christopher H. van Dyck et al.   NEW ENGLAND JOURNAL OF MEDICINE

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease

(2021) Joel Simrén et al.   Alzheimers & Dementia

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease

(2021) Pratishtha Chatterjee et al.   Translational Psychiatry

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study

(2021) Adam M. Brickman et al.   Alzheimers & Dementia

APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function

(2021) Monica Xiong et al.   Science Translational Medicine

Plasma P‐tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease

(2021) Joyce R. Chong et al.   Alzheimers & Dementia

Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation

(2021) Pratishtha Chatterjee et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease

(2021) Elisabeth H. Thijssen et al.   Scientific Reports

Alzheimer disease

(2021) David S. Knopman et al.   Nature Reviews Disease Primers

Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau

(2021) Shorena Janelidze et al.   Alzheimers & Dementia

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease

(2021) Joana B Pereira et al.   BRAIN

Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias

(2021) Daniel Alcolea et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

(2021) Elisabeth H Thijssen et al.   LANCET NEUROLOGY

Off-label use of aducanumab for cerebral amyloid angiopathy

(2021) Steven M Greenberg et al.   LANCET NEUROLOGY

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

(2021) Sebastian Palmqvist et al.   NATURE MEDICINE

Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy–Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study

(2021) Laura Antolini et al.   NEUROLOGY

Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy

(2021) Michel J. Grothe et al.   NEUROLOGY

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations

(2021) Nicholas C. Cullen et al.   Nature Communications

A multicentre validation study of the diagnostic value of plasma neurofilament light

(2021) Nicholas J. Ashton et al.   Nature Communications

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

(2021) Shorena Janelidze et al.   JAMA Neurology

Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes

(2021) Michelle M. Mielke et al.   JAMA Neurology

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

(2021) Charlotte E Teunissen et al.   LANCET NEUROLOGY

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques

(2021) Yan Li et al.   NEUROLOGY

Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes

(2021) Jordan D. Marks et al.   Alzheimers Research & Therapy

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231

(2021) Sherif Bayoumy et al.   Alzheimers Research & Therapy

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

(2021) Andréa L. Benedet et al.   JAMA Neurology

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Perivascular spaces in the brain: anatomy, physiology and pathology

(2020) Joanna M. Wardlaw et al.   Nature Reviews Neurology

Neurofilaments: neurobiological foundations for biomarker applications

(2020) Arie R Gafson et al.   BRAIN

CSF p-tau/Aβ42 ratio and brain FDG-PET may reliably detect MCI “imminent” converters to AD

(2020) Roberto Santangelo et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy

(2020) Gargi Banerjee et al.   JOURNAL OF ALZHEIMERS DISEASE

Plasma Amyloid Concentration in Alzheimer’s Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer’s Disease Cases from Controls

(2020) Insa Feinkohl et al.   JOURNAL OF ALZHEIMERS DISEASE

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage

(2020) Breton M. Asken et al.   JOURNAL OF ALZHEIMERS DISEASE

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

(2020) Inge M. W. Verberk et al.   Alzheimers Research & Therapy

Neurofilament light chain predicts risk of recurrence in cerebral amyloid angiopathy-related intracerebral hemorrhage

(2020) Xin Cheng et al.   Aging-US

Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis

(2020) Steffi De Meyer et al.   Alzheimers Research & Therapy

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

(2020) Shorena Janelidze et al.   JAMA Neurology

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease

(2019) Oliver Preische et al.   NATURE MEDICINE

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease

(2019) Andrea Vergallo et al.   Alzheimers & Dementia

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

(2019) Niklas Mattsson et al.   JAMA Neurology

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

(2019) Suzanne E. Schindler et al.   NEUROLOGY

Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis

(2019) Yinan Zhao et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

(2019) Sebastian Palmqvist et al.   JAMA Neurology

Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications

(2019) Yannick Chantran et al.   Frontiers in Immunology

Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer’s Disease

(2019) Pratishtha Chatterjee et al.   JOURNAL OF ALZHEIMERS DISEASE

Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways

(2019) Steven M. Greenberg et al.   Nature Reviews Neurology

Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer’s Disease

(2018) Charlotte E. Teunissen et al.   JOURNAL OF ALZHEIMERS DISEASE

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy

(2018) Andreas Charidimou et al.   NEUROLOGY

Plasma amyloid as pre-screener for the earliest Alzheimer's pathological changes

(2018) Inge M.W. Verberk et al.   ANNALS OF NEUROLOGY

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

(2017) Niklas Mattsson et al.   JAMA Neurology

Distinct deposition of amyloid-β species in brains with Alzheimer’s disease pathology visualized with MALDI imaging mass spectrometry

(2017) Nobuto Kakuda et al.   Acta Neuropathologica Communications

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

(2016) Sebastian Palmqvist et al.   BRAIN

Comparison of cerebrospinal fluid profiles in Alzheimer’s disease with multiple cerebral microbleeds and cerebral amyloid angiopathy-related inflammation

(2016) Akio Kimura et al.   JOURNAL OF NEUROLOGY

Cerebral amyloid angiopathy-related inflammation: A potentially reversible cause of dementia with characteristic imaging findings

(2016) Prashant Raghavan et al.   JOURNAL OF NEURORADIOLOGY

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases

(2016) Mehtap Bacioglu et al.   NEURON

Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration

(2016) Henrik Zetterberg   NEURON

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

(2016) Henrik Zetterberg et al.   JAMA Neurology

Cerebral Amyloid Angiopathy-Related Atraumatic Convexal Subarachnoid Hemorrhage: An ARIA before the Tsunami

(2015) Eva Martínez-Lizana et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Inflammatory Cerebral Amyloid Angiopathy, Amyloid-β–Related Angiitis, and Primary Angiitis of the Central Nervous System

(2015) Aimen Moussaddy et al.   STROKE

Cerebral Amyloid Angiopathy: Emerging Concepts

(2015) Masahito Yamada   Journal of Stroke

Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for amyloid-modifying therapies

(2013) Fabrizio Piazza et al.   ANNALS OF NEUROLOGY

Increased Levels of Antigen-Bound β-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer’s Disease Patients

(2013) Madalina Maftei et al.   PLoS One

Sleep Drives Metabolite Clearance from the Adult Brain

(2013) L. Xie et al.   SCIENCE

Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome

(2013) Benjamin Lam et al.   Alzheimers Research & Therapy

Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria

(2012) Dimitri Renard et al.   JOURNAL OF NEUROLOGY

Plasma ß-Amyloid Levels in Cerebral Amyloid Angiopathy-Associated Hemorrhagic Stroke

(2012) Mar Hernandez-Guillamon et al.   Neurodegenerative Diseases

Anti-A  autoantibodies in the CSF of a patient with CAA-related inflammation: A case report

(2011) J. C. DiFrancesco et al.   NEUROLOGY

Elevation of β-Amyloid 1-42 Autoantibodies in the Blood of Amnestic Patients With Mild Cognitive Impairment

(2010) Daniela Storace et al.   ARCHIVES OF NEUROLOGY

Cerebrospinal fluid amyloid β40is decreased in cerebral amyloid angiopathy

(2009) Marcel M. Verbeek et al.   ANNALS OF NEUROLOGY

Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease

(2009) M. Britschgi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

β-Amyloid, Blood Vessels, and Brain Function

(2009) Eric E. Smith et al.   STROKE